Bildkälla: Stockfoto

Xbrane Biopharma Q4 2023: Navigating muddy waters - Redeye

Redeye comments on Xbrane’s year-end report, updates its forecasts following recent developments, and adjusts its valuation for the rights issue which has had large implications on the share price.

Redeye comments on Xbrane’s year-end report, updates its forecasts following recent developments, and adjusts its valuation for the rights issue which has had large implications on the share price.
Börsvärldens nyhetsbrev
ANNONSER